Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 386-393 , September 2010

Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells

  • Margaret A. Calciano

      Affiliations

    • ExonHit Therapeutics Inc, Gaithersburg, MD, USA
    • ,
  • Weiyin Zhou

      Affiliations

    • ExonHit Therapeutics Inc, Gaithersburg, MD, USA
    • ,
  • Peter J. Snyder

      Affiliations

    • Lifespan Affiliated Hospitals & Alpert Medical School of Brown University, Providence, RI, USA
    • ,
  • Richard Einstein

      Affiliations

    • ExonHit Therapeutics Inc, Gaithersburg, MD, USA
    • Corresponding Author InformationCorresponding author. Tel.: 240-683-7073; Fax: 240-683-7060.

References 

  1. Mann DM, Yates PO. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol. 1986;5:147–158
  2. Davies B, Andrewes D, Stargatt R, Ames D, Tuckwell V, Davis S. Tacrine in Alzheimer's disease. Lancet. 1989;2:163–164
  3. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358–369
  4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593
  5. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211–225
  6. Husain MM, Trevino K, Siddique H, McClintock SM. Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat. 2008;4:765–777
  7. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  8. Gupta M, Kaur H, Grover S, Kukreti R. Pharmacogenomics and treatment for dementia induced by Alzheimer's disease. Pharmacogenomics. 2008;9:895–903
  9. Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics. 2009;19:635–646
  10. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase k-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics. 2008;18:289–298
  11. Cacabelos R. Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3:303–333
  12. Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73:761–767
  13. Reitz C, Mayeux R. Endophenotypes in normal brain morphology and Alzheimer's disease: a review. Neuroscience. 2009;164:174–190
  14. Zhou W, Calciano M, Jordan H, Brenner M, Johnson S, Wu D, et al. High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity. BMC Genet. 2009;10:63
  15. Pando MP, Kotraiah V, McGowan K, Bracco L, Einstein R. Alternative isoform discrimination by the next generation of expression profiling microarrays. Expert Opin Ther Targets. 2006;10:613–625
  16. Fehlbaum P, Guihal C, Bracco L, Cochet O. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Res. 2005;33:e47
  17. Heinzen EL, Yoon W, Weale ME, Sen A, Wood NW, Burke JR, et al. Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease. Genome Biol. 2007;8:R32
  18. Einstein R, Jordan H, Zhou W, Brenner M, Moses EG, Liggett SB. Alternative splicing of the g protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors. Proc Natl Acad Sci USA. 2008;105:5230–5235
  19. Kozyrev SV, Abelson A, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, et al. Functional variants in the b-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:211–216
  20. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–233
  21. Boue S, Letunic I, Bork P. Alternative splicing and evolution. Bioessays. 2003;25:1031–1034
  22. Calarco JA, Xing Y, Cáceres M, Calarco JP, Xiao X, Pan Q, et al. Global analysis of alternative splicing differences between humans and chimpanzees. Genes Dev. 2007;21:2963–2975
  23. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. Panther: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13:2129–2141
  24. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 2006;34(web server issue):W645–W650
  25. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21:453–478
  26. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002;56:441–446
  27. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, et al. DNA mutation associated with the human butyrylcholinesterase k-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992;50:1086–1103
  28. Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day IN, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase k gene variation. J Neurol Neurosurg Psychiatry. 2005;76:640–643
  29. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006;16:771–774
  30. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation. 2008;5:51
  31. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol. 2004;148:162–171
  32. Noh M, Koh S, Kim Y, Kim HY, Cho GW, Kim SH. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem. 2009;108:1116–1125
  33. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther. 2003;306:772–777
  34. Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci Lett. 2005;391:17–21
  35. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact. 2008;175:222–226
  36. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther. 2005;315:1346–1353
  37. Zhou X, Patel AR, Perez F, Jurivich DA. Acetylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl Res. 2009;153:132–141
  38. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359–1362
  39. Miller LD, Liu ET. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res. 2007;9:206
  40. Kruse JJ, Stewart FA. Gene expression arrays as a tool to unravel mechanisms of normal tissue radiation injury and prediction of response. World J Gastroenterol. 2007;13:2669–2674
  41. Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299:1574–1587

 Conflict of interest: The majority of authors are employees of ExonHit Therapeutics, a drug discovery and diagnostic development company. The manuscript utilizes a major technology used for internal and extramural programs for the company. A conflict of interest exists due to the financial interest that the authors have in ExonHit Therapeutics, Inc.

PII: S1552-5260(10)00003-8

doi: 10.1016/j.jalz.2009.12.004

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 386-393 , September 2010

Article Tools

* Image Usage & Resolution